Investigating the potential of microRNAs as biomarkers for bladder cancer diagnosis and prognosis
DOI:
https://doi.org/10.22034/JATE.2024.110Keywords:
Biomarker; Bladder cancer; Chemoresistance; miRNA; RadioresistanceAbstract
Bladder cancer (BC) is a significant health concern, with high incidence and mortality rates, particularly among men. The molecular mechanisms underlying BC development and progression, including DNA damage response (DDR) and microRNAs (miRNAs) dysregulation, play crucial roles in tumorigenesis. This paper aims to explore the role of miRNAs in BC, focusing on their association with tumor formation, invasion, and response to chemotherapy and radiotherapy. The study categorizes miRNAs based on their impact on BC pathogenesis, highlighting both down-regulated tumor suppressor miRNAs and up-regulated miRNAs promoting tumor development. Additionally, the paper discusses the potential of miRNAs as biomarkers for predicting chemo-resistance and radio-resistance in BC patients, elucidating how miRNA expression profiles can influence treatment outcomes and patient survival. Furthermore, this article reviews the current modalities of cancer treatment, including chemotherapy, targeted therapies, and radiotherapy, emphasizing the importance of personalized medicine approaches. Overall, this review highlights the importance of miRNAs in BC pathophysiology and their potential as therapeutic targets or diagnostic tools in improving patient outcomes.
References
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020;8(1).
Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis. 2000;21(3):379-85.
Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 2017;24(6):233-43.
Hu H, Gatti RA. MicroRNAs: new players in the DNA damage response. J Mol Cell Biol. 2011;3(3):151-8.
Suszynska M, Machowska M, Fraszczyk E, Michalczyk M, Philips A, Galka-Marciniak P, et al. CMC: Cancer miRNA Census–a list of cancer-related miRNA genes. Nucleic Acids Research. 2024;52(4):1628-44.
Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015;2015:125094.
Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016;13(12):734-52.
P D. Bartel, Metazoan MicroRNAs. Cell. 2018(173(1): ):20–51.
Seo HA, Moeng S, Sim S, Kuh HJ, Choi SY, Park JK. MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies. Cells. 2019;9(1).
Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka H, Yamasaki T, et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun. 2012;417(1):588-93.
Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka H, et al. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One. 2014;9(2):e84311.
Zhang XF, Zhang XQ, Chang ZX, Wu CC, Guo H. microRNA145 modulates migration and invasion of bladder cancer cells by targeting Ncadherin. Mol Med Rep. 2018;17(6):8450-6.
Fujii T, Shimada K, Tatsumi Y, Hatakeyama K, Obayashi C, Fujimoto K, et al. microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer. 2015;15:818.
Ding ZS, He YH, Deng YS, Peng PX, Wang JF, Chen X, et al. MicroRNA-34a inhibits bladder cancer cell migration and invasion, and upregulates PTEN expression. Oncol Lett. 2019;18(5):5549-54.
Huang X, Zhu H, Gao Z, Li J, Zhuang J, Dong Y, et al. Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. J Biol Chem. 2018;293(18):6693-706.
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009;460(7254):529-33.
Santulli G. microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis. Adv Exp Med Biol. 2015;887:53-77.
Wang H, Li Q, Niu X, Wang G, Zheng S, Fu G, et al. miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett. 2017;13(1):435-40.
Xu T, Qin L, Zhu Z, Wang X, Liu Y, Fan Y, et al. MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin alpha5. Oncotarget. 2016;7(19):27445-57.
Wang S, Wu G, Han Y, Song P, Chen J, Wu Y, et al. miR-124 regulates STAT3-mediated cell proliferation, migration and apoptosis in bladder cancer. Oncol Lett. 2018;16(5):5875-81.
Wang X, Wu Q, Xu B, Wang P, Fan W, Cai Y, et al. MiR-124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine-tuning UHRF1. FEBS J. 2015;282(22):4376-88.
Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu DH, et al. MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014;14:70.
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009;15(16):5060-72.
Shui-Qing Wu H-QH, Ye Kang, Ran Xu, Lei Zhang, Xiao-Kun Zhao, Xuan Zhu. MicroRNA-200c affects bladder cancer angiogenesis by regulating the Akt2/mTOR/HIF-1 axis. Transl Cancer Res. 2019;8, No 8 (December 2019) 2713–24.
Liu L, Qiu M, Tan G, Liang Z, Qin Y, Chen L, et al. miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3. J Transl Med. 2014;12:305.
Liu W, Qi L, Lv H, Zu X, Chen M, Wang J, et al. MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy. BMC Cancer. 2015;15:92.
Wang JR, Liu B, Zhou L, Huang YX. MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer. Cancer Biomark. 2019;24(2):159-72.
Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M, et al. Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 2016;107(9):1233-42.
Yan T, Ye XX. MicroRNA-328-3p inhibits the tumorigenesis of bladder cancer through targeting ITGA5 and inactivating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2019;23(12):5139-48.
Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851-60.
Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, et al. MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 2013;441(4):976-81.
Zhang DZ, Lau KM, Chan ES, Wang G, Szeto CC, Wong K, et al. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One. 2014;9(7):e100793.
Zhang S, Zhang C, Liu W, Zheng W, Zhang Y, Wang S, et al. MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3. Int J Oncol. 2015;47(4):1351-60.
Vallo S, Rutz J, Kautsch M, Winkelmann R, Michaelis M, Wezel F, et al. Blocking integrin beta1 decreases adhesion in chemoresistant urothelial cancer cell lines. Oncol Lett. 2017;14(5):5513-8.
Cao Z, Xu L, Zhao S, Zhu X. The functions of microRNA-124 on bladder cancer. Onco Targets Ther. 2019;12:3429-39.
Zhang L, Wang CZ, Ma M, Shao GF. MiR-15 suppressed the progression of bladder cancer by targeting BMI1 oncogene via PI3K/AKT signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(20):8813-22.
Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, et al. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS One. 2013;8(7):e67686.
Xu M, Li J, Wang X, Meng S, Shen J, Wang S, et al. MiR-22 suppresses epithelial-mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop. Cell Death Dis. 2018;9(2):209.
Yu G, Yao W, Xiao W, Li H, Xu H, Lang B. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res. 2014;33:779.
Zhou XU, Qi L, Tong S, Cui YU, Chen J, Huang T, et al. miR-128 downregulation promotes growth and metastasis of bladder cancer cells and involves VEGF-C upregulation. Oncol Lett. 2015;10(5):3183-90.
Yan L, Wang Y, Liang J, Liu Z, Sun X, Cai K. MiR-301b promotes the proliferation, mobility, and epithelial-to-mesenchymal transition of bladder cancer cells by targeting EGR1. Biochem Cell Biol. 2017;95(5):571-7.
Wang Y, Xu Z, Wang X. miRNA-373 promotes urinary bladder cancer cell proliferation, migration and invasion through upregulating epidermal growth factor receptor. Exp Ther Med. 2019;17(2):1190-5.
Mao XW, Xiao JQ, Li ZY, Zheng YC, Zhang N. Effects of microRNA-135a on the epithelial-mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3beta through the Wnt/beta-catenin signaling pathway. Exp Mol Med. 2018;50(1):e429.
Mao XP, Zhang LS, Huang B, Zhou SY, Liao J, Chen LW, et al. Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer. J Transl Med. 2015;13:86.
Song T, Zhang X, Zhang L, Dong J, Cai W, Gao J, et al. miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. J Cancer Res Clin Oncol. 2013;139(7):1189-98.
Wei XC, Lv ZH. MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition via TGFbeta1/Smad2 signaling pathway in human bladder cancer. Onco Targets Ther. 2019;12:5937-45.
Mitash N, Agnihotri S, Tiwari S, Agrawal V, Mandhani A. MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer. Indian J Urol. 2017;33(4):283-90.
Baudino TA. Targeted Cancer Therapy: The Next Generation of Cancer Treatment. Curr Drug Discov Technol. 2015;12(1):3-20.
Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38(1):156.
Ji W, Sun B, Su C. Targeting MicroRNAs in Cancer Gene Therapy. Genes (Basel). 2017;8(1).
Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009-18.
Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. 2000;164(3 Pt 1):627-32.
Oncology ASoC. Bladder Cancer: Treatment Options. 10/2017 Accessed at wwwcancernet/cancer-types/bladder-cancer/treatment-options on January 18. 2019.
Chou R, Selph SS, Buckley DI, Gustafson KS, Griffin JC, Grusing SE, et al. Treatment of muscle-invasive bladder cancer: A systematic review. Cancer. 2016;122(6):842-51.
Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19(1):89-93.
Yong Hyu Goh JY, Jung Hyun Noh, Chan Kim. Emerging targeted therapies in advanced bladder cancer. Translational Cancer Research. 2017;6(Supplement 4).
Kischkel FC, Eich J, Meyer CI, Weidemuller P, Krapfl J, Yassin-Kelepir R, et al. New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples. PeerJ. 2017;5:e3030.
Brasseur K, Gevry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 2017;8(3):4008-42.
Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem. 2008;312(1-2):71-80.
Magee P, Shi L, Garofalo M. Role of microRNAs in chemoresistance. Ann Transl Med. 2015;3(21):332.
Kozinn SI, Harty NJ, Delong JM, Deliyiannis C, Logvinenko T, Summerhayes IC, et al. MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines. Genes Cancer. 2013;4(1-2):61-9.
Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, et al. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep. 2011;25(6):1721-9.
Xiao J, Niu S, Zhu J, Lv L, Deng H, Pan D, et al. miR223p enhances multichemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep. 2018;39(6):2731-40.
Deng Y, Bai H, Hu H. rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression. Biochem Biophys Res Commun. 2015;458(2):321-7.
Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20(7):1990-2000.
Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer. 2012;130(11):2526-38.
Li H, Yu G, Shi R, Lang B, Chen X, Xia D, et al. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer. 2014;13:8.
Liu X, Liu X, Wu Y, Fang Z, Wu Q, Wu C, et al. MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis. Cell Physiol Biochem. 2018;48(1):87-98.
Zhang Q, Zhuang J, Deng Y, Yang L, Cao W, Chen W, et al. miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness. Theranostics. 2017;7(19):4777-90.
Tan Y, Zhang T, Zhou L, Liu S, Liang C. MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit. 2019;25:1323-35.
Liu J, Wang H, Wang Y, Li Z, Pan Y, Liu Q, et al. Repression of the miR-93-enhanced sensitivity of bladder carcinoma to chemotherapy involves the regulation of LASS2. Onco Targets Ther. 2016;9:1813-22.
Luan T, Fu S, Huang L, Zuo Y, Ding M, Li N, et al. MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells. Exp Cell Res. 2018;373(1-2):188-97.
Bu Q, Fang Y, Cao Y, Chen Q, Liu Y. Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway. Mol Med Rep. 2014;10(4):2203-9.
Li B, Xie D, Zhang H. MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2. J Cancer. 2019;10(12):2628-34.
Cao J, Wang Q, Wu G, Li S, Wang Q. miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a. Int Urol Nephrol. 2018;50(10):1811-9.
Chen J, Li Y, Li Z, Cao L. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling. J Biochem Mol Toxicol. 2020;34(4):e22452.
Zhuang J, Shen L, Yang L, Huang X, Lu Q, Cui Y, et al. TGFbeta1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer. Theranostics. 2017;7(12):3053-67.
Lei Y, Hu X, Li B, Peng M, Tong S, Zu X, et al. miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit. 2014;20:1850-7.
Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, et al. The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta. 2015;1852(3):520-8.
Lin SR, Yeh HC, Wang WJ, Ke HL, Lin HH, Hsu WC, et al. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells. J Cell Biochem. 2017;118(6):1563-73.
Lv L, Deng H, Li Y, Zhang C, Liu X, Liu Q, et al. The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death Dis. 2014;5:e1402.
Zhou J, Duan H, Xie Y, Ning Y, Zhang X, Hui N, et al. MiR-193a-5p Targets the Coding Region of AP-2alpha mRNA and Induces Cisplatin Resistance in Bladder Cancers. J Cancer. 2016;7(12):1740-6.
Pan J, Li X, Wu W, Xue M, Hou H, Zhai W, et al. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 2016;382(1):64-76.
Shindo T, Niinuma T, Nishiyama N, Shinkai N, Kitajima H, Kai M, et al. Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer. Oncotarget. 2018;9(36):24457-69.
Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z, et al. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One. 2015;10(11):e0143441.
Liu J, Bi J, Li Z, Li Z, Liu X, Kong C. miR214 reduces cisplatin resistance by targeting netrin1 in bladder cancer cells. Int J Mol Med. 2018;41(3):1765-73.
Li P, Yang X, Cheng Y, Zhang X, Yang C, Deng X, et al. MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. Cell Physiol Biochem. 2017;41(3):921-32.
Zeng LP, Hu ZM, Li K, Xia K. miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells. J Cell Mol Med. 2016;20(3):559-67.
Li Y, Shan Z, Liu C, Yang D, Wu J, Men C, et al. MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer. Biochemistry (Mosc). 2017;82(4):474-82.
Du L, Zhang L, Sun F. Puerarin Inhibits the Progression of Bladder Cancer by Regulating circ_0020394/miR-328-3p/NRBP1 Axis. Cancer Biother Radiopharm. 2020.
Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-9.
Cannan WJ, Pederson DS. Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin. J Cell Physiol. 2016;231(1):3-14.
Kavanagh JN, Redmond KM, Schettino G, Prise KM. DNA double strand break repair: a radiation perspective. Antioxid Redox Signal. 2013;18(18):2458-72.
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-88.
Fornalski KW. Radiation adaptive response and cancer: From the statistical physics point of view. Phys Rev E. 2019;99(2-1):022139.
Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther. 2009;8(8):665-70.
Li F, Zhou K, Gao L, Zhang B, Li W, Yan W, et al. Radiation induces the generation of cancer stem cells: A novel mechanism for cancer radioresistance. Oncol Lett. 2016;12(5):3059-65.
Kurth I, Hein L, Mabert K, Peitzsch C, Koi L, Cojoc M, et al. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget. 2015;6(33):34494-509.
Ahmed KM, Dong S, Fan M, Li JJ. Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res. 2006;4(12):945-55.
Korpela E, Vesprini D, Liu SK. MicroRNA in radiotherapy: miRage or miRador? Br J Cancer. 2015;112(5):777-82.
Cellini F, Morganti AG, Genovesi D, Silvestris N, Valentini V. Role of microRNA in response to ionizing radiations: evidences and potential impact on clinical practice for radiotherapy. Molecules. 2014;19(4):5379-401.
Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W, et al. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One. 2009;4(7):e6377.
Czochor JR, Glazer PM. microRNAs in cancer cell response to ionizing radiation. Antioxid Redox Signal. 2014;21(2):293-312.
Javanmardi S, Aghamaali MR, Abolmaali SS, Mohammadi S, Tamaddon AM. miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance. Curr Gene Ther. 2017;16(6):375-89.
Xu R, Li H, Wu S, Qu J, Yuan H, Zhou Y, et al. MicroRNA-1246 regulates the radio-sensitizing effect of curcumin in bladder cancer cells via activating P53. Int Urol Nephrol. 2019;51(10):1771-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The Journal of Applied Tissue Engineering
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
